Treatment of atopic dermatitis in infancy;Tratamiento de la dermatitis atópica en la infancia

Actas Dermo-Sifiliograficas

Volumn 94, Issue 6, 2003, Pages 345-355

  Baselga, Eulalia ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; AMOXICILLIN; ASCOMYCIN; ATIZORAM; AZATHIOPRINE; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; ERYTHROMYCIN; FLUTICASONE PROPIONATE; GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 2; ITRACONAZOLE; MACROLIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHODIESTERASE INHIBITOR; PIMECROLIMUS; TACROLIMUS;

ADRENAL SUPPRESSION; ATOPIC DERMATITIS; ECZEMA; HUMAN; IMMUNOMODULATION; INFANT; INFANT DISEASE; INFECTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NEUTROPENIA; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRURITUS; PUVA; REVIEW; SIDE EFFECT; SKIN ATROPHY; STEROID THERAPY; SUPERINFECTION;

EID: 0041880704     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(03)76704-0     Document Type: Review

References (120)

1. Williams HC. Epidemiology of atopic dermatitis. Clin Exp Dermatol 2000;25:522-9.
2. Schultz LF. Atopic dermatitis: An increasing problem. Pediatr Allergy Immunol 1996;7:51-3.
3. Roth HL, Kierland RR. The natural history of atopic dermatitis. Arch Dermatol 1964;89:209-14.
4. Graham-Brown RA. Atopic dermatitis: Predictions, expectations, and outcomes. J Am Acad Dermatol 2001;45: S61-S3.
5. Finlay AY. Qualitty of life in atopic dermatitis. J Am Acad Dermatol 2002;S64-S6.
6. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants' Dermatitis Quality of Life Index. Br J Dermatol 2001;144:104-10.
7. Linnet J, Jemec GB. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol 1999;140:268-72.
8. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-75.
9. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000;80:430-4.
10. Su JC, Kemp AS, Varigos CA, Nolan TM. Atopic eczema: Its impact on the family and financial cost. Arch Dis Child 1997;76:159-62.
11. Herd RM. The financial impact on families of children with atopic dermatitis. Arch Dermatol 2002;138:819-20.
12. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002;46:361-70.
13. Ohya Y, Williams H, Steptoe A, et al. Psychosocial factors and adherence to treatment advice in childhood atopic dermatitis. J Invest Dermatol 2001;117:852-7.
14. Staab D, Von Rueden U, Kehrt R, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol 2002;13:84-90.
15. Chavigny JM, Adiceom F, Bernier C, Debons M, Stalder JF. Ecole de l'atopie, evaluation d'une experience d'education therapeutique chez 40 malades. Ann Dermatol Venereol 2002;129:1003-7.
16. Cambazard F, Michel JL. Les traitements actuels de la dermatite atopique chez l'enfant. Revue du Praticien 2000;50:1355-60.
17. Sidbury R, Hanifin JM. Old, new, and emerging therapies for atopic dermatitis. Dermatol Clin 2000;18:1-11.
18. Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000;25:559-66.
19. Thestrup-Pedersen K. Treatment principles of atopic dermatitis. J Eur Acad Dermatol Venereol 2002;16:1-9.
20. Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol 2000;1:41-6.
21. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-60.
22. Sator PG, Schmidt JB, Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol 2003;48:352-8.
23. Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998;78:27-30.
24. Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: A study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 1995;75:429-33.
25. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997;14:321-4.
26. Visscher MO, Chatterjee R, Ebel JP, LaRuffa AA, Hoath SB. Biomedical assessment and instrumental evaluation of healthy infant skin. Pediatr Dermatol 2002;19:473-81.
27. Yamamoto A, Serizawa S, Ito M, Sato Y. Stratum corneum lipid abnormalities in atopic dermatitis. Arch Dermatol Res 1991;283:219-23.
28. Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: An etiologic factor in atopic dry skin? J Invest Dermatol 1991;96:523-6.
29. Man MM, Feingold KR, Thornfeldt CR, Elias PM. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996;106:1096-101.
30. Coderch L, López O, De La MA, Parra JL. Ceramides and skin function. Am J Clin Dermatol 2003;4:107-29.
31. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198-208.
32. Loden M, Barany E. Skin-identical lipids versus petrolatum in the treatment of tape-stripped and detergent-perturbed human skin. Acta Derm Venereol 2000;80:412-5.
33. Eedy DJ, Graham-Brown RA. Atopiform dermatitis: What's in a name? Br J Dermatol 2002;147:415-7.
34. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of house dust-mite allergen avoidance on atopic dermatitis. Lancet 1996;347:15-8.
35. Ricci G, Patrizi A, Specchia F, et al. Effect of host dust mite avoidance measures in children with atopic dermatitis. Br J Dermatol 2000;143:379-84.
36. Gutgesell C, Heise S, Seubert S, et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol 2001;145:70-4.
37. Peroni DG, Chatzimichail A, Boner AL. Food allergy: What can be done to prevent progression to asthma? Ann Allergy Asthma Immunol 2002;89:44-51.
38. Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: Pathophysiology, epidemiology, diagnosis, and management. J Allerg Clin Immunol 1999;104: S114-S22.
39. Sampson HA, Scanlon SM. Natural history of food hypersensitivity in children with atopic dermatitis. J Pediatr 1989;115:23-7.
40. Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: Evaluation of 113 patients. J Pediatr 1985;107:669-75.
41. Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998;101:E8.
42. Niggemann B. Atopy Patch Test (APT)-its role in diagnosis of food allergy in atopic dermatitis. Indian J Pediatr 2002;69:57-9.
43. Turjanmaa K. "Atopy patch tests" in the diagnosis of delayed food hypersensitivity. Allerg Immunol (Paris) 2002;34:95-7.
44. Lever R. The role of food in atopic eczema. J Am Acad Dermatol 2001;45:S57-S60.
45. Zeiger RS, Heller S. The development and prediction of atopy in high-risk children: Follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Immunol 1995;95:1179-90.
46. Zeiger RS. Dietary manipulations in infants and their mothers and the natural course of atopic disease. Pediatr Allergy Immunol 1994;5:33-43.
47. Zeiger RS. Prevention of food allergy in infancy. Ann Allergy 1990;65:430-42.
48. Zeiger RS, Heller S, Mellon MH, et al. Effect of combined maternal and infant food-allergen avoidance on development of atopy in early infancy: A randomized study. J Allergy Clin Immunol 1989;84:72-89.
49. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: Clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002;3:47-58.
50. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984;1:246-53.
51. McLean CJ, Lobo RF, Brazier DJ. Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 1995;345:330.
52. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child 1982;136:274-5.
53. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999;140:1114-21.
54. Faergemann J, Christensen O, Sjovall P, et al. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2000;14:393-6.
55. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528-37.
56. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-6.
57. Goodyear HM, Spowart K, Harper JI. "Wet-wrap" dressings for the treatment of atopic eczema in children. Br J Dermatol 1991;125:604.
58. Devillers AC, Waard-van der Spek FB, Mulder PG, Oranje AP. Treatment of refractory atopic dermatitis using "wet-wrap" dressings and diluted corticosteroids: Results of standardized treatment in both children and adults. Dermatology 2002;204:50-5.
59. Wolkerstorfer A, Visser RL, De Waard van der Spek FB, Mulder PG, Oranje AP. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: Influence of corticosteroid dilution. Br J Dermatol 2000;143:999-1004.
60. Ruzicka T, Assmann T, Homey B. Tacrolimus: The drug for the turn of the millennium? Arch Dermatol 1999;135:574-80.
61. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002;16:100-14.
62. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-21.
63. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998;102:63744.
64. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy. J Am Acad Dermatol 2001;44:S28-S38.
65. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44:S47-S57.
66. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55.
67. Reitamo S, Van Leent EJ, Ho VC, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allerg Clin Immunol 2002;109:539-46.
68. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:S58-S64.
69. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136:999-1006.
70. Koo JYM, Fleischer A PDMC. Tacrolimus Ointment 0,1 % Is Safe and Effective in the Treatment for Atopic Dermatitis: Final Results of a Large (Over 7000 Patients) Open-Label Study. Poster p 22. Annual Meeting of the American Academy of Dermatology. San Francisco.
71. Paller A, Hanifin J, Eichenfield L, Clark R. Tacrolimus Ointment Is Safe and Effective Treatment for Atopic Dermatitis Lond Term (More Than 3 Years). Poster p 24 Annual Meeting of the American Academy of Dermatology. San Francisco March 20-26, 2003.
72. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children. J Am Acad Dermatol 1998;38:69-76.
73. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial. J Invest Dermatol 1998;111:396-8.
74. Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety. J Am Acad Dermatol 2001;44:S39-S46.
75. Kawakami T, Soma Y, Morita E, et al. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology 2001;203:32-7.
76. Fleischer AB Jr, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002;47:562-70.
77. Remitz A, Kyllonen H, Granlund H, Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001;107:196-7.
78. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dennatol 2001;144:781-7.
79. Griffiths CE. Ascomycin: An advance in the management of atopic dermatitis. Br J Dermatol 2001;144:679-81.
80. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002;204:63-8.
81. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998;134:805-9.
82. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1 % in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
83. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1 % in the treatment of atopic dermatitis in infants. J Pediatr 2003;142:155-62.
84. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
85. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-84.
86. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002;205:271-7.
87. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-94.
88. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study. Br J Dermatol 2001;144:507-13.
89. Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J, Cipamyflline SG. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol 2002;147:299-307.
90. Hanifin J, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vivo anti-inmlammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51-6.
91. Abeck D, Mempel M. Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998;139(Suppl 53):13-6.
92. Leung DY. Atopic dermatitis and the immune system: The role of superantigens and bacteria. J Am Acad Dermatol 2001;45:S13-S6.
93. Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol 2000;105:782-7.
94. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999;135:1522-5.
95. Van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. Arch Dermatol 1987;123:166-7.
96. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-40.
97. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol 1997;136:527-30.
98. Berth-Jones J, Graham-Brown RA, Marks R, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997;136:76-81.
99. Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993;129:422-30.
100. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: A Multicenter study. J Am Acad Dermatol 1996;34:1016-21.
101. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: Short course versus continuous therapy. Br J Dermatol 2000;142:52-8.
102. Harper JI, Berth-Jones J, Camp RD, et al. Cyclosporin for atopic dermatitis in children. Dermatology 2001;203:3-6.
103. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: A double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002;147:324-30.
104. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002;147:308-15.
105. Buckley DA, Baldwin P, Rogers S. The use of azathioprine in severe adult atopic eczema. J Eur Acad Dermatol Venereol 1998;11:137-40.
106. Lear JT, English JS, Jones P, Smith AG. Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol 1996;35:642-3.
107. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol 2001;26:369-75.
108. Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001;144:638-9.
109. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil [comment]. Br J Dermatol 1999;141:175-6.
110. Grundmann-Kollmann M, Kaufmann R, Zollner TM. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001;145:351-2.
111. Hansen ER, Buus S, Deleuran M, Andersen KE. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2000;143:1324-6.
112. Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000;143:385-91.
113. Guss S, Portnoy J. Methotrexate treatment of severe asthma in children. Pediatrics 1992;89:635-9.
114. Jolles S, Hughes J, Whittaker S. Dermatological uses of high dose intravenous immunoglobulin. Arch Dermatol 1998;134:80-6.
115. Jolles S, Hughes J, Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: A report of three patients and review of the literature. Br J Dermatol 2000;142:551-4.
116. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2002;27:3-7.
117. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002;147:518-22.
118. Atherton DJ, Carabott F, Glover MT, Hawk JL. The role of psoralen photochemotherapy (PUVA) in the treatment of severe atopic eczema in adolescents. Br J Dermatol 1988;118:791-5.
119. Sheehan MP, Atherton DJ, Norris P, Hawk J. Oral psoralen photochemotherapy in severe childhood atopic eczema: An update. Br J Dermatol 1993;129:431-6.
120. Der-Petrossian M, Seeber A, Honigsmann H, Tanew A. Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol 2000;142:39-43.